Literature DB >> 2845097

Sequence-dependent effect of camptothecin on human topoisomerase I DNA cleavage.

E Kjeldsen1, S Mollerup, B Thomsen, B J Bonven, L Bolund, O Westergaard.   

Abstract

We have studied the effect of the antitumor drug, camptothecin, on the interaction of human topoisomerase I with DNA at the sequence level. At a low molar ratio of enzyme to DNA, cleavage is prominent and unique, located at a previously described hexadecameric recognition sequence, while a number of strong additional cleavage sites appear in the presence of the drug. Camptothecin stimulates cleavage at the recognition sequence less than twofold, whereas cleavage at the additional sites is stimulated up to 200-fold. Camptothecin greatly enhances the stability of the cleavable complexes formed at the additional sites, whereas the complex formed at the hexadecameric sequence is only marginally affected. Cleavage was eliminated at certain sites in the presence of camptothecin. Taken together these observations demonstrate that at least three types of potential eukaryotic topoisomerase I cleavage sites can be distinguished by the use of camptothecin. Comparison of the sequences at the additional cleavage sites in the presence of camptothecin reveals that the most frequently cleaved dinucleotide is TG with no consensus for the flanking nucleotides.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2845097     DOI: 10.1016/0022-2836(88)90462-7

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  20 in total

1.  A human topoisomerase I cleavage complex is recognized by an additional human topisomerase I molecule in vitro.

Authors:  K Søe; G Dianov; H P Nasheuer; V A Bohr; F Grosse; T Stevnsner
Journal:  Nucleic Acids Res       Date:  2001-08-01       Impact factor: 16.971

2.  Topoisomerase I is preferentially associated with normal SV40 replicative intermediates, but is associated with both replicating and nonreplicating SV40 DNAs which are deficient in histones.

Authors:  J J Champoux
Journal:  Nucleic Acids Res       Date:  1992-07-11       Impact factor: 16.971

3.  In vivo sequencing of camptothecin-induced topoisomerase I cleavage sites in human colon carcinoma cells.

Authors:  C Pondarré; D Strumberg; A Fujimori; R Torres-León; Y Pommier
Journal:  Nucleic Acids Res       Date:  1997-10-15       Impact factor: 16.971

4.  Optimum DNA relaxation reaction conditions for calf thymus DNA-topoisomerase I are determined by specific enzyme features.

Authors:  S Coderoni; M Paparelli; G L Gianfranceschi
Journal:  Mol Biol Rep       Date:  1990-11       Impact factor: 2.316

5.  Sequence dependent modulating effect of camptothecin on the DNA-cleaving activity of the calf thymus type I topoisomerase.

Authors:  I I Gromova; V L Buchman; R A Abagyan; A V Ulyanov; I B Bronstein
Journal:  Nucleic Acids Res       Date:  1990-02-11       Impact factor: 16.971

6.  Transcription of adenovirus and HeLa cell genes in the presence of drugs that inhibit topoisomerase I and II function.

Authors:  J Schaak; P Schedl; T Shenk
Journal:  Nucleic Acids Res       Date:  1990-03-25       Impact factor: 16.971

7.  Mapping in vivo topoisomerase I sites on simian virus 40 DNA: asymmetric distribution of sites on replicating molecules.

Authors:  S E Porter; J J Champoux
Journal:  Mol Cell Biol       Date:  1989-02       Impact factor: 4.272

8.  Topoisomerase I sites cluster asymmetrically at the ends of the simian virus 40 core origin of replication.

Authors:  S Tsui; M E Anderson; P Tegtmeyer
Journal:  J Virol       Date:  1989-12       Impact factor: 5.103

9.  The basis for camptothecin enhancement of DNA breakage by eukaryotic topoisomerase I.

Authors:  S E Porter; J J Champoux
Journal:  Nucleic Acids Res       Date:  1989-11-11       Impact factor: 16.971

10.  Specific cleavage of chicken alpha A-globin and human c-Ha-ras genes by two molecular forms of calf thymus topoisomerase I.

Authors:  I B Bronstein; I I Gromova; S V Razin
Journal:  Mol Cell Biochem       Date:  1991-03-13       Impact factor: 3.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.